Dr. Charles F. Carpenter, M.D.
Preventive Medicine & Public Health (Public Health & General Preventive Medicine Physician)
At a glance
- In the NPI registry since
- 2008
Licensed in California since 2003, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Public Health & General Preventive Medicine Physician primary
CA license A83564 (first issued 2003; current) · TX license W9850 (first issued 2026; active) -
Addiction Medicine (Preventive Medicine) Physician
CA license A83564 (first issued 2003; current) · TX license W9850 (first issued 2026; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Map: Preventive Medicine & Public Health per capita by county →
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Buprenorphine-Naloxone (buprenorphine hcl/naloxone hcl) Other prescribers in Sacramento, CA | 33 |
| Buprenorphine Hcl Other prescribers in Sacramento, CA | 21 |
| Gabapentin Other prescribers in Sacramento, CA | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $13.66 in total to this clinician.
| Indivior Inc. | $13.66 |
|---|
| Food and Beverage | $13.66 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 4 companies. The companies reported $602,574 in research payments for these studies, mostly to the institutions running them.
- WEV-MVA-002
Bavarian Nordic A/s - A Phase IIb Randomised, Double-blind, Placebocontrolled Study to Evaluate the Efficacy, Safety and Tolerability of Coadministration of AZD9550 and AZD6234 in Participants Living With Obesity or Overweight with Co-morb…
AstraZeneca Pharmaceuticals LP - AIRE Mobile Unit Mobile Prescreening Protocol
AstraZeneca UK Limited - A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age
ModernaTX, Inc. · Completed · NCT05575492 - A Phase II Randomised Double blind Placebo controlled Study to Evaluate the Efficacy Safety and Tolerability of AZD6234 in Participants Living with Obesity or Overweight with Comorbidity
AstraZeneca Pharmaceuticals LP - A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19
ModernaTX, Inc. · Completed · NCT05815498 - A phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like part…
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.